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We examined the paradoxical hypothesis that the alpha receptor inverse agonist 
doxazosin might produce beneficial effects in allergic rhinitis. 
Objectives: 
To evaluate single and chronic dosing effects of doxazosin on nasal airflow and 
symptoms in allergic rhinitis.  
Methods: 
15 patients randomized to receive 3-5 weeks of oral doxazosin 4mg daily or placebo 
in cross-over fashion. Measurements were made at baseline and after first and last 
doses.  
Results: 
There was a fall in peak nasal inspiratory flow (PNIF) between baseline vs first dose 
of doxazosin: mean difference -19 L/min (95%CI -35 to -2) P=0.03, with recovery 
between first and last doses: 21 L/min (95%CI 7 to 34) P= 0.006. Nasal visual 
analogue scale (VAS) and blockage scores were worse between baseline vs first 
dose of doxazosin: mean difference VAS -10 mm (95%CI -18 to - 2) p=0.02, 
blockage -0.7 (95%CI -1.3 to -0.1) p=0.02; with recovery between first and last 
doses:  VAS 15mm (95%CI 4 to 25) p=0.009, blockage 1.1 (95%CI 0.5 to 1.6) 
p=0.001. The oxymetazoline dose response for PNIF was blunted after single vs 
chronic dosing: mean difference -17 L/min (95%CI -30 to -4) P=0.01.  Heart rate and 
diastolic blood pressure showed the same pattern. There was a significant difference 
between doxazosin and placebo for nasal blockage score and heart rate after single 




There was a disconnect between single and chronic dosing effects of doxazosin for 
nasal symptoms, oxymetazoline response and cardiovascular outcomes, in turn 
suggesting   alpha-1 receptor up-regulation . 
(www.clinicaltrials.gov # NCT01946035) 
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ANOVA:  analysis of variance 
95%CI: 95% confidence interval 
DRC:  dose response curve 
MID:  minimal important difference 
Nasal NO: nasal nitric oxide 
PNIF:  peak nasal inspiratory flow 
RQLQ: rhino-conjunctivitis quality of life questionnaire 
SEM:  standard error of mean 
TNS4:  total nasal symptom score 
T1/2 :  elimination half life 





Current management guidelines for allergic rhinitis advocate the use of nasal 
corticosteroids and anti-histamines as first line therapy [1].  However despite such 
treatment there is an unmet need with many patients remaining symptomatic in 
terms of persistent nasal blockage, especially in those patients who have reduced 
airway patency due to inferior turbinate hypertrophy. 
Alpha-receptor agonists such as oxymetazoline are available without prescription 
and provide effective acute decongestant relief, mediated by direct venoconstriction 
of the nasal sinusoids and by vasoconstriction of afferent arterioles and arterio-
venous shunts, leading to a reduction in blood flow to the sinusoids. However their 
repeated use is associated with a rapid tachyphylaxis of response due alpha-
receptor down regulation and G-protein uncoupling, resulting in desensitization of 
response [2]. In addition to tachyphylaxis of the vasoconstrictor response there is 
also an associated increase in nasal airway hyper-reactivity and rebound worsening 
of nasal congestion, resulting in the so called syndrome of rhinitis medicamentosa 
[3]. Hence alpha-agonists are only recommended for decongestant use on a 
temporary short term basis in patients with allergic rhinitis, for example to aide nasal 
breathing during an acute viral episode. 
In healthy volunteers, after repeated dosing with oxymetazoline, there is a reduction 
in nasal airway patency as reflected by a fall peak nasal inspiratory flow (PNIF) along 
with a rightward shift in the dose response curve (DRC) to oxymetazoline due to 
alpha-receptor down regulation [4]. A single dose of the alpha-1 antagonist prazosin 
produces an acute fall in PNIF as well as blunting of the PNIF dose-response curve 
(DRC) to oxymetazoline [4]. This suggests that the predominant vasomotor response 
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in the human nose is mediated alpha-1 receptors in keeping with previous in vitro 
studies [5].   
In healthy volunteers the dorsal hand vein vasoconstrictor DRC to the alpha-1 
agonist phenylephrine was shifted by seven fold to the right after the first dose of the 
alpha-1 antagonist terazosin compared to baseline, but after 4 weeks of terazosin 
the dose response to phenylephrine returned back to baseline, in turn indicating that 
alpha-1 receptor up regulation occurs during chronic dosing [6, 7].  
These data have in turn led to a novel paradoxical pharmacological hypothesis [8], 
namely that chronic dosing with a selective alpha-1 receptor antagonist doxazosin 
might be beneficial in allergic rhinitis by producing alpha-1 receptor up regulation and 
associated resensitisation of alpha receptor mediated responsiveness. Doxazosin 
exhibits strong inverse agonist activity [9] at the alpha-1 receptor and may therefore 
be able to inhibit constitutive unliganded receptor activity in addition to its antagonist 
activity by inhibiting the receptor when activated by ligand. The presence of inverse 
agonist activity also appears to be related to the propensity for inducing up regulation 
of alpha-1 receptors [10].  
Such a paradigm shift in thinking from agonist to antagonist (or inverse agonist) has 
already been seen in heart failure, where chronic exposure beta-agonists was found 
to be unhelpful due to beta-receptor down-regulation and associated desensitization 
of cardiac inotropic response. The use of beta-receptor antagonists in heart failure 
was contra-indicated due an acute worsening in cardiac function after first dose 
exposure. It was not until clinical trials looked past this initial deterioration that the 
improvements in cardiac function, morbidity and mortality were seen in heart failure 
during chronic dosing with beta-blockers [11, 12]. Interestingly a similar paradoxical 
scenario has also been recently postulated in asthma [13], whereby chronic 
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exposure to long acting beta-2 agonists may in certain genetically susceptible 
individuals cause worsening of disease control [14] and associated airway hyper-
reactivity [15]. There have been conflicting results in asthma with beta-blockers 
which exhibit inverse agonist activity in that chronic dosing open label nadolol 
improved airway hyper-reactivity [16], while placebo controlled trials with propranolol 
have failed to show any benefits [17, 18]. 
The underlying hypothesis is that one might perhaps expect opposite beneficial 
effects on the nasal vasculature upon repeated exposure to the inverse agonist 
doxazosin as compared to the agonist oxymetazoline . Hence  the purpose of 
present proof of concept study was to evaluate the putative disconnect between 
single and chronic dosing effects of alpha-1 receptor blockade with doxazosin on 
nasal airflow and symptoms in allergic rhinitis, as a consequence of inverse agonist 
activity and associated alpha-1 receptor up-regulation. We also measured the 
response to oxymetazoline as a surrogate to follow alpha-1 receptor regulation.  
In addition we wanted to assess what might happen in the presence of an acute 
inflammatory nasal insult induced by a bolus dose of histamine after stopping 
doxazosin and how this might influence the subsequent recovery in response to 
oxymetazoline.  As we have previously shown that topical corticosteroid may 
produce alpha-1 receptor up-regulation and augment the response to oxymetazoline 
[4], we therefore decided to obviate this potential confounding effect by stopping any 
nasal corticosteroid therapy for the duration of the study. Anti-histamines were also 
stopped for the duration so as not to interfere with the histamine challenges. Hence 
we enrolled patients with mild allergic rhinitis who might be able to manage without 
such treatments for the duration of the study, instead using nasal cromoglycate 
spray on demand.  
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Materials and Methods  
We enrolled patients with a physician based diagnosis of mild allergic rhinitis [19] 
who had at least one positive skin prick test to a panel of common aeroallergens. 
Patients with a history of seasonal allergic rhinitis were evaluated out with the pollen 
season. Rigid nasal endoscopy was performed at screening to exclude those 
patients who had evidence of a deviated nasal septum (>50%), obstructive inferior 
turbinate hypertrophy, obstructive adenoidal hypertrophy or nasal polyposis. Patients 
were required to exhibit at least a 20 L/min and 20% reversibility in PNIF during a 
DRC to  oxymetazoline using a diluent (baseline) followed by cumulative doses of 
25ug, 50ug and 100ug (sum of both nostrils) at 15 minute intervals, as previously 
described [4]. 
Patients were also required to be able to withhold nasal steroids and anti-histamines 
for the duration of the study. Patients with a systolic blood pressure less than 100mm 
Hg were excluded along with any other vasodilators which might interact with 
doxazosin to adversely lower blood pressure.  Informed written consent was 
obtained from all patients and the Tayside medical ethics committee approved the 
protocol (Ethics 13/ES/0010, Clinical Trials.gov NCT01946035, EudraCT 2012-
005035-85).  
A randomized double blind placebo controlled cross-over design was employed 
(Figure 1) where patients received either prolonged release Doxazosin (Cardozin XL, 
Arrow Generics Ltd, Stevenage ,UK) 4mg once daily in the evening or identical 
(over-encapsulated) placebo (Royal Free Hospital, London UK) for 3-5 weeks. There 
was a 1-3 week run-in and washout period in between randomized treatments, the 
rationale being that a minimum duration of 1 week would exceed a period of five 
elimination half lives (t 1/2 = 9 hours) for doxazosin [20]. The prolonged release 
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formulation was chosen to improve tolerability in terms of the propensity for 
hypotension in association with a smoother pharmacokinetic profile.   
Measurements were made at baseline after run-in and washout and at 12 hours after 
the first and last doses of each randomized treatment including PNIF and symptoms, 
along with a DRC to oxymetazoline (25ug, 50ug and 100ug cumulative dose). The 
construction of the oxymetazoline DRC at 12 hours after dosing was chosen to 
coincide with the mid point of the daily dosing interval when using the prolonged 
release formulation, to ensure maximal receptor occupancy.  
At baseline and at each of the single and chronic dosing visits the following were 
also recorded: total nasal symptom score (TNS4) comprising blockage, sneezing, 
itching and discharge - ranging from 0 (absence of symptoms) to 3 (severe) within 
each domain (i.e. a total score of 0-12), global nasal visual analog scale (VAS) 
symptom score ranging from 0 (absence of symptoms) to 100mm (very severe 
symptoms) [21], supine/erect heart rate and blood pressure. Juniper rhino-
conjunctivitis quality of life score (mini RQLQ) [22] and nasal nitric oxide (NO) [23] 
were measured at baseline and after chronic dosing.  
In addition at 36 hours after the last dose patients attended for a further separate 
visit where they were given a bolus dose of nasal histamine (6.4mg) after initial 
diluent followed by a subsequent oxymetazoline DRC during recovery post challenge 
(25ug,50ug,100ug cumulative dose). Throughout the study patients also recorded 
domiciliary diary cards for PNIF. Patients were permitted to use nasal Cromoglycate 
spray 2% on demand during the entire study having stopped their usual treatment 
with either nasal steroids or anti-histamines.  
PNIF measurements were taken as the best of three measures from an In-check 
flow meter (Clement Clarke International Ltd, Harlow, England). Technique was 
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evaluated to ensure a seated posture, horizontal positioning of the meter, correct 
restoration of the reading to zero, a closed mouth, and an adequate mask seal while 
making a maximal nasal inspiration. Nasal NO was measured using a 
chemiluminescence analyzer (NIOX; Aerocrine AB, Stockholm, Sweden) under 
standard conditions using  the standard aspiration technique recommended by the 
American Thoracic Society guidelines [24] using a unilateral nasal olive, breath-
holding, and velum closure at a flow rate of 50 ml/s. 
 
Statistical Analysis  
 
The study was powered at 80% to detect a minimal important difference of 5l/min 
[25] (within subject SD 7 L/min) in the primary end point of PNIF with an alpha error 
of 0.05 (two tailed). Baseline values after run-in and washout were compared paired 
Students T tests. An overall repeated measures analysis of variance (ANOVA) was 
applied to evaluate visit based effects for PNIF and other secondary outcomes, 
followed by paired Students T tests to compare different time points. An overall 
repeated measures ANOVA was used to compare serial time points for the overall 






15 patients completed per protocol comprising 7 males, mean (SEM) age: 37 (3) 
years, PNIF: 135 (12) L/min, VAS 19 (5) mm, nasal blockage score 0.9 (0.3), TNS4 
score 3.2 (0.8), with a mean of three positive skin prick tests for each individual. All 
patients were taking anti-histamines, either regular or on demand, two were taking 
nasal steroids, and one was taking leukotriene receptor antagonist. None were 
taking alpha-agonists. The participant flow is shown in Figure 2. 
 
Visit based nasal outcomes: 
Data for all visit based outcomes in response to randomized treatments are 
summarized in Table 1.  Baseline values after run-in and washout prior to 
randomized treatments were not significantly different for any of the outcomes. There 
was a significant overall effect (P=0.01) on PNIF comparing serial time points. There 
was a fall in PNIF between baseline and the first dose of doxazosin: mean difference 
-19 L/min (95%CI -35 to -2) P=0.03, along with recovery back to baseline between 
the first and last doses: mean difference 21 L/min (95%CI 7 to 34) P= 0.006 (Figure 
3). Differences in PNIF between placebo and doxazosin were not significant after 
single: mean difference 18 L/min (95%CI -1 to 37) P=0.06, or chronic dosing: mean 
difference 12 L/min (95%CI -6 to 30) P=0.18.  
There was a significant overall effect (P=0.04) on global nasal VAS score comparing 
serial time points. The VAS score (0-100mm) showed worsening between baseline 
and the first dose of doxazosin: mean difference -10mm (95%CI -18 to -2) p=0.02, 
with recovery back to baseline between first and last doses: mean difference 15 mm 
(95%CI 4 to 25) p=0.009 (Figure 3). The VAS score was not significantly different 
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after the first dose of placebo verses doxazosin: mean difference -9 mm (95%CI -18 
to 1) P=0.07.  
The nasal blockage score (0-3) also showed the same pattern in terms of a 
significant overall effect (P=0.001) and also comparing baseline and first dose with 
doxazosin: mean difference -0.7 (95%CI -1.3 to -0.1) p=0.02 and between first and 
last doses: mean difference 1.1 (95%CI 0.5 to 1.6) p=0.001 (Figure 3). There was 
also a difference in blockage score between placebo and doxazosin after the first 
dose: mean difference -0.7 (95% CI -1.4 to -0.02) p=0.04.  
The overall TNS4 score (0-12) was only significant comparing the first and last doses 
of doxazosin: mean difference 1.5 (95%CI 0.1 to 3.0) p=0.04, and there was no 
difference between placebo and doxazosin. No difference was observed in the other 
TNS4 domains including the rhinorrhea score. 
Mini RQLQ scores were not different comparing values between baseline and 
chronic dosing with doxazosin: (1.59 verses 1.29) mean difference -0.30 (95%CI -
0.70 to 0.10) P=0.13, or with placebo: (1.67 verses 1.58) mean difference:-0.09 
(95%CI -0.72 to 0.54) P=0.76.Chronic dosing values for placebo and doxazosin were 
also not different.  
There were no differences in geometric mean nasal NO values between chronic 
dosing with doxazosin (376 ppb) verses respective baseline (295ppb): geometric 
mean fold difference 1.28 (95%CI 0.90 to1.82) P=0.16, or between chronic dosing 
with placebo (304 ppb) versus respective baseline (318ppb): geometric mean fold 





The oxymetazoline DRC for PNIF was relatively blunted after single compared to 
chronic dosing with doxazosin: mean difference -17 L/min (95%CI -30 to -4) P=0.01 
(Figure 4), but no such difference in oxymetazoline DRC was seen after single vs 
chronic dosing with placebo: mean difference -4 L/min (95%CI -16 to 7) P=0.41.  The 
oxymetazoline DRC was not different when comparing placebo and doxazosin after 
chronic dosing: mean difference 1 L/min (95%CI -10 to13) P=0.83. 
The magnitude of the acute fall in PNIF in response to histamine challenge was not 
altered comparing placebo vs doxazosin after chronic dosing: mean difference 6 
L/min (95%CI -7 to18) P=0.31 (Figure 5). The subsequent PNIF recovery with 
oxymetazoline post histamine challenge was also no different comparing placebo vs 
doxazosin: mean difference 4 L/min (95%CI -16 to 25) P=0.66. 
 
Visit based cardiovascular outcomes: 
There was a significant overall effect on supine (P=0.002) and erect (P=0.001) heart 
rate as well as on erect diastolic blood pressure (P=0.04) comparing serial time 
points.  Heart rate was increased from baseline after the first dose of doxazosin: 
supine mean difference 9 beats/min (95%CI 3 to 14) P=0.003, erect mean 
difference: 12 beats/min  (95%CI 5 to 20) P=0.004, and recovered back to baseline 
between the first and the last doses: supine mean difference -9 beats/min (95%CI -
15 to -2) P=0.01, erect mean difference -13 beats/min (95%CI -23 to -3) P=0.01. 
There was a significant difference in the first dose effect between doxazosin and 
placebo for supine heart rate: mean difference 6 beats /min (95%CI 1 to 11) P=0.03 
and for erect rate: mean difference 12 beats/min (95%CI 5 to 19) P=0.004. Erect 
diastolic blood pressure was lowered after the first dose of doxazosin compared to 
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baseline: mean difference -6 mmHg (95%CI -11 to -1) P=0.04, along with recovery 
between first and last doses: mean difference: 5mmHg (95%CI 1- to 10) P=0.02. 
 
Domiciliary PNIF: 
There were no differences in mean domiciliary PNIF values between pre-treatment 
baseline (run-in/washout) and the last week of doxazosin: (139 verses 142 L/min) 
mean difference -1L/min (95% CI -13 to 11) P=0.82, or between pre and post values 
for placebo: (139 verses 143 L/min) mean difference -4 L/min (95%CI -23 to 16) 






The results of this proof of concept study showed that alpha-blockade resulted in 
worsening of nasal airflow (as PNIF) and symptoms (as global VAS and nasal 
blockage scores) after the single but not chronic dosing with doxazosin. Thus, after 
the last dose PNIF, VAS and blockage scores had all returned back to baseline. We 
observed a significant difference between doxazosin and placebo for nasal blockage 
score and heart rate after single but not chronic dosing. 
The worsening in nasal airflow and symptoms after initial exposure is due to acute 
vasodilatation consequent upon blockade of the prevailing sympathetic vasomotor 
tone in the nasal sinusoids. The difference between single and repeated dosing is 
most likely explained by adaptive up regulation of alpha-1 receptors in the nasal 
vasculature [7] ,although we did not measure nasal alpha receptor density in the 
present study.  The same disconnect between single and chronic dosing was also 
seen with cardiovascular responses.  It is worth mentioning that there were no 
differences when comparing baselines between visits after run-in and washout, 
confirming there were no carryover effects between the randomized treatment arms. 
This is to be expected since the duration of washout of at least one week (i.e. 168 
hours) greatly exceeds a period of five elimination half-lives for doxazosin (i.e. 45 
hours) [20].  
It is pertinent to distinguish between what may be statistically significant and clinical 
relevant differences.  Hence the observed difference between single and chronic 
dosing in VAS score of 15mm is less than the minimal important difference (MID) of 
23mm [26], while the corresponding difference in overall TNS4 score of 1.5 exceeds 
the MID of 0.55 [25], and for PNIF the difference of  21 L/min exceeds the MID of 5 
L/min [25].  
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We also observed that the acute decongestant response to oxymetazoline was 
relatively blunted after the first compared to the last dose with doxazosin. This infers 
that resensitization of alpha-1 receptors occurred at 12 hours after the last dose of 
doxazosin, which would correspond to a period of maximal receptor occupancy at 
steady-state with the modified release formulation of doxazosin.  In the dorsal hand 
vein model the phenylephrine response returned back to baseline after 4 weeks of 
treatment with terazosin having been initially blunted after the first dose [6]. Indeed 
the oxymetazoline DRC after the last dose of doxazosin was not different from 
placebo, suggesting that full recovery of alpha-1 receptors had occurred. Serial 
measurement of nasal alpha receptor binding density would however be required to 
confirm this assumption.  
The same disconnect seen for nasal airflow and symptoms was also observed when 
comparing single and chronic dosing effects upon heart rate and on erect diastolic  
blood pressure. The increase in heart rate after the first dose of doxazosin is due to 
reflex vagal withdrawal following peripheral vasodilatation.  However no patients 
reported any symptoms attributable to postural hypotension which could reflect use 
of the prolonged release formulation given to relatively young subjects. 
We also performed a bolus histamine challenge to try and mimic the scenario where 
patients might be exposed to an acute nasal insult such as an allergen, virus or 
chemical. This showed that the acute fall in PNIF in response to histamine as well as 
the subsequent oxymetazoline recovery were no different at 36 hours after the last 
dose of doxazosin as compared to placebo. We performed the challenge at a time 
when there should be diminished residual receptor occupancy, since 36 hours 
equates to a period of four elimination half-lives for doxazosin [20]. It seems unlikely 
that at 36 hours there is any persistent alpha-1 receptor up-regulation given that 
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there was no evidence of any rebound effect on histamine PNIF fall or altered 
oxymetazoline recovery after stopping doxazosin.  In the dorsal hand vein model 
there was found to be no difference in response to phenylephrine at 72 hours after 
stopping terazosin as compared to baseline [6].  
We chose doxazosin not only for its availability as a well tolerated modified release 
preparation but also because of its strong inverse agonist activity [9]. As with beta-
blockers such as carvedilol which exhibit inverse activity in heart failure [12], we 
considered that this pharmacological property of doxazosin might also prove to be 
beneficial in allergic rhinitis. It might also be interesting to evaluate the effects of 
topical administration of doxazosin which would achieve much higher local 
concentrations in nasal mucosa, although such a formulation is not available. 
The clinical implication of these findings is that at least in the medium term over 3-5 
weeks the use of oral alpha blockade does not result in any therapeutic benefit for 
patients with mild allergic rhinitis in terms of nasal airway patency or symptoms. For 
such patients who are taking concomitant alpha blockers for the indications of 
hypertension or prostatic hypertrophy, there appears to be no cogent rationale for 
stopping treatment.  
We stopped nasal steroids for the duration of the study so as to obviate any potential 
confounding effect due to alpha receptor up-regulation [4].  Hence we were only able 
to include patients with mild allergic rhinitis who could manage without nasal steroids 
and anti-histamines for the duration of the study.  We appreciate that we may not be 
able to reliably extrapolate our results to what might happen in the presence of 
concomitant nasal steroids in more severe patients.   
17 
We appreciate the limitations of our proof of concept study in mild patients with 
allergic rhinitis. First, we did not have a control group which might comprise either 
healthy volunteers or perhaps patients with non allergic rhinitis. 
Second, we can not extrapolate our results to what might happen in more severe 
patients taking concomitant intranasal corticosteroids. Finally we did not measure 
nasal alpha receptor binding density and therefore can only postulate about serial 
receptor regulation in response to doxazosin. Nonetheless the nasal and 
cardiovascular outcomes all going in the same direction would tend to suggest that 
tachyphylaxis had occurred as a consequence of receptor up-regulation. 
In conclusion, we observed a disconnect between single and chronic dosing effects 
of doxazosin for nasal airflow, symptoms, oxymetazoline response and 
cardiovascular outcomes, in keeping with up regulation of alpha-1 receptors.  Further 
long term studies with doxazosin may be warranted  perhaps in patients with non 
allergic rhinitis, or in more severe patients with allergic rhinitis taking intranasal 
corticosteroids  ,to explore the therapeutic potential of its inverse agonist activity in 
terms of effects on nasal airflow, symptoms and quality of life. 
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Table 1. Data for visit based outcomes according to randomized treatments 
 Placebo Doxazosin 
 Baseline Single dose  Chronic dose  Baseline  Single dose  Chronic dose  
PNIF (L min-1) 157(16) 155(16) 170(17) 156(15) 137(14)* 158(14)† 
VAS (mm) 23(6) 25(6) 20(4) 24(5) 34(5)* 19(4)† 
Nasal blockage score (0-3)  1.3(0.3) 1.4(0.3) 1.3(0.2) 1.4(0.2) 2.1(0.3)* # 1.1(0.2)† 
Overall TNS4 (0-12) 3.6(0.8) 3.5(0.7) 3.2(0.4) 4.1(0.8) 4.3(0.8) 2.8(0.5)† 
Supine heart rate (bpm) 73(4) 74(3) 71(3) 72(3) 80(4)* # 72(4)† 
Erect heart rate (bpm) 82(4) 84(3) 82(3) 84(3) 96(5)* # 83(3)† 
Supine systolic BP 
(mmHg) 
131(3) 135(4) 133(5) 131(4) 133(3) 132(3) 
Erect systolic BP (mmHg) 130(3) 129(4) 133(4) 132(4) 125(3) 130(4) 
Supine diastolic BP 
(mmHg) 
79(3) 78(3) 79(3) 79(3) 78(2) 80(3) 
Erect diastolic BP 
(mmHg) 
81(2) 80(3) 84(3) 85(3) 79(2)* 84(3)† 
Data are presented as means (SEM)  
*denotes a significant difference between baseline and single dosing for the effect of doxazosin 
 †denotes a significant difference between single and chronic dosing for the effect of doxazosin 







Figure Legends  
 
Figure 1  
Flow chart for study visits. A placebo controlled randomized cross-over design was 
used. Baseline measures after run-in and washout were performed at Visits 2/6, 
while single dose effects were measured at visits 3/7 and chronic dose effects at 
visits 4/8 (at 12 hours post dose). At each of these visits an oxymetazoline dose 
response curve was also performed.  At visits 5/9 after the last dose, a bolus 
histamine challenge was performed along with subsequent recovery in response 
oxymetazoline (at 36 hours post dose).  
 
Figure 2 
Consort diagram showing participant flow  
 
Figure 3 
Effects of single and chronic dosing with doxazosin or placebo on (a) peak nasal 
inspiratory flow (PNIF L/min), (b) nasal blockage score (0-3 units), (c) global visual 
analog scale (VAS) score (0-100 mm). Asterisk denotes a significant difference 
between baseline and single dosing, while cross denotes a significant difference 
between single and chronic dosing for the effect of doxazosin. Hash sign denotes a 
significant difference in blockage score between placebo and doxazosin after the first 
dose. Values are shown as means and SEM.  
 
Figure 4  
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Cumulative oxymetazoline (OXY) dose response curve (DRC) showing PNIF 
response after single and chronic doses of (a) placebo and (b) doxazosin. Asterisk 
denotes a significant difference in terms of relative blunting of overall oxymetazoline 
PNIF dose response comparing first verses last doses of doxazosin. There was no 
significant difference in dose response between first and last doses of placebo. 
Values are shown as means and SEM. 
 
Figure 5  
Effect of a bolus histamine challenge and subsequent recovery on PNIF in response 
to oxymetazoline at 36 hours after the last dose of doxazosin or placebo. There was 
no significant difference between doxazosin and placebo comparing the PNIF fall in 
response to histamine or the subsequent oxymetazoline recovery. Values are shown 
as means and SEM. 
 
